Nuveen Asset Management, LLC Exact Sciences Corp Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 1,224,565 shares of EXAS stock, worth $59.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,224,565

Previous 985,634 24.24%

Holding current value

$59.4 Million

Previous $67.1 Million 2.53%

% of portfolio

0.02%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$49.33 - $71.97 $11.8 Million - $17.2 Million	238,931 Added 24.24%	1,224,565 $68.8 Million
Q3 2024 Nov 14, 2024	BUY	$42.43 - $70.83 $3.44 Million - $5.74 Million	80,979 Added 8.95%	985,634 $67.1 Million
Q2 2024 Aug 09, 2024	SELL	$41.33 - $74.26 $905,085 - $1.63 Million	-21,899 Reduced 2.36%	904,655 $38.2 Million
Q1 2024 May 13, 2024	SELL	$56.27 - $73.77 $546,606 - $716,601	-9,714 Reduced 1.04%	926,554 $64 Million
Q4 2023 Feb 14, 2024	BUY	$59.06 - $75.72 $10.8 Million - $13.9 Million	183,105 Added 24.31%	936,268 $69.3 Million
Q3 2023 Nov 14, 2023	SELL	$65.94 - $99.04 $239,032 - $359,020	-3,625 Reduced 0.48%	753,163 $51.4 Million
Q2 2023 Aug 14, 2023	SELL	$62.68 - $95.05 $545,127 - $826,649	-8,697 Reduced 1.14%	756,788 $71.1 Million
Q1 2023 May 15, 2023	BUY	$47.19 - $70.77 $4.64 Million - $6.95 Million	98,250 Added 14.72%	765,485 $51.9 Million
Q4 2022 Feb 14, 2023	BUY	$30.35 - $53.15 $6.37 Million - $11.2 Million	209,965 Added 45.92%	667,235 $33 Million
Q3 2022 Nov 14, 2022	SELL	$31.97 - $49.37 $451,640 - $697,449	-14,127 Reduced 3.0%	457,270 $14.9 Million
Q2 2022 Aug 15, 2022	SELL	$35.61 - $76.23 $4.07 Million - $8.71 Million	-114,314 Reduced 19.52%	471,397 $18.6 Million
Q1 2022 May 16, 2022	BUY	$57.56 - $82.54 $1.6 Million - $2.29 Million	27,719 Added 4.97%	585,711 $37.4 Million
Q4 2021 Feb 14, 2022	BUY	$72.5 - $100.68 $2.21 Million - $3.07 Million	30,477 Added 5.78%	557,992 $43.4 Million
Q3 2021 Nov 12, 2021	SELL	$90.24 - $124.05 $32.8 Million - $45.1 Million	-363,378 Reduced 40.79%	527,515 $50.4 Million
Q2 2021 Aug 16, 2021	BUY	$93.66 - $139.27 $2.17 Million - $3.23 Million	23,216 Added 2.68%	890,893 $111 Million
Q1 2021 May 17, 2021	SELL	$116.57 - $155.01 $22.2 Million - $29.5 Million	-190,271 Reduced 17.98%	867,677 $114 Million
Q4 2020 May 17, 2021	BUY	$99.61 - $142.12 $3.69 Million - $5.27 Million	37,082 Added 3.63%	1,057,948 $140 Million
Q4 2020 Feb 16, 2021	SELL	$99.61 - $142.12 $11 Million - $15.6 Million	-110,111 Reduced 9.74%	1,020,866 $135 Million
Q3 2020 Nov 16, 2020	BUY	$72.92 - $102.01 $3.29 Million - $4.6 Million	45,112 Added 4.15%	1,130,977 $115 Million
Q2 2020 Aug 14, 2020	BUY	$55.75 - $92.75 $19 Million - $31.6 Million	340,334 Added 45.65%	1,085,865 $94.4 Million
Q1 2020 May 14, 2020	SELL	$37.9 - $104.44 $11.3 Million - $31 Million	-297,270 Reduced 28.51%	745,531 $43.2 Million
Q4 2019 Feb 14, 2020	BUY	$77.66 - $99.74 $4.11 Million - $5.28 Million	52,909 Added 5.34%	1,042,801 $96.4 Million
Q3 2019 Nov 14, 2019	SELL	$90.37 - $122.49 $3.99 Million - $5.41 Million	-44,197 Reduced 4.27%	989,892 $89.5 Million
Q2 2019 Aug 15, 2019	BUY	$89.51 - $118.04 $92.6 Million - $122 Million	1,034,089 New	1,034,089 $122 Million
Q2 2018 Aug 14, 2018	SELL	$37.84 - $69.96 $1.27 Million - $2.36 Million	-33,671 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$39.82 - $57.53 $391,311 - $565,347	9,827 Added 41.21%	33,671 $1.36 Million
Q4 2017 Feb 14, 2018	BUY	$46.49 - $60.51 $563,272 - $733,139	12,116 Added 103.31%	23,844 $0
Q3 2017 Nov 14, 2017	BUY	$37.05 - $47.12 $434,522 - $552,623	11,728	11,728 $553,000

Others Institutions Holding EXAS

# of Institutions

644

Shares Held

157M

Call Options Held

1.83M

Put Options Held

1.56M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $8.58B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Exact Sciences Corp Transaction History